Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13979833 | 0.84 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL1682976 | 0.83 | KCNN4 (0.64) | KCNN4SRCCES1TSHRMAPT | |
| Triphenylacetic Acid Methyl Ester SCHEMBL7258414 | 0.82 | KCNN4 (1.00) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL5227343 | 0.81 | KCNN4 (0.62) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL9199545 | 0.81 | KCNN4 (0.62) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL10812516 | 0.80 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL16732028 | 0.80 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL728471 | 0.80 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL4022191 | 0.80 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT | |
| SCHEMBL28157758 | 0.80 | KCNN4 (0.67) | KCNN4SRCCES1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734976-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RyCarma Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006617-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-11746178-B2 | Polymer production method and radical polymerization initiating group-containing compound | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-09-05 | — | — | US | disclosed |
| US-11746178-B2 | Polymer production method and radical polymerization initiating group-containing compound | DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2023-09-05 | — | — | US | disclosed |
| EP-3424960-B1 | POLYMER PRODUCTION METHOD AND RADICAL POLYMERIZATION INITIATING GROUP-CONTAINING COMPOUND | DAINICHISEIKA COLOR CHEM (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3604354-B1 | PRODUCTION METHOD FOR POLYMER | DAINICHISEIKA COLOR CHEM (JP) | 2022-02-02 | — | — | EP | disclosed |
| EP-3604354-A1 | PRODUCTION METHOD FOR POLYMER, COMPOUND CONTAINING RADICAL-POLYMERIZATION INITIATION GROUP, AND POLYMER | Dainichiseika Color & Chemicals Mfg. Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| EP-1751131-B1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | KCNN4 4624/4885SRC 4386/4885CES1 226/4885 |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | KCNN4 4350/4885SRC 4691/4885CES1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.